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CV at infusion rates of 1ml/minute at various balloon inﬂations (BI). Mesenchymal
SC at concentration of 5x106/ml were tested for viability using trypan blue pre and
post injection through the SLC and MLC during BI of 6, 8, 10 and 12 atm. Numerical
modeling was used to determined ﬂuid dispersion at different ﬂuid velocities,
viscosities and exit distances.
Results: Collapsing of the SLC infusion lumen was noted during BI while no changes
were noted in the MLC infusion lumen. Computational ﬂuid dynamic calculations in
the SLC demonstrated signiﬁcant increase of 2979 Pascal in ﬂuid shear stress. As
balloon pressure increased in the SLC, the infusion lumen collapsed, whereas ﬂuid
shear stress in the MLC was 43 Pascal. CV decreased in the SLC at a ﬂow rate of
1ml/min from (97.5 to 91.7)%, (95.7 to 94.1)%, (94.9 to 86.8)%, (97.9 to 76.9)% at
6, 8, 10 and 12 atm respectively (p¼0.047) while no signiﬁcant change in CV
occurred using MLC resulting in (93.5 to 92.3)%, (95 to 93.1)%, (95 to 94.6)%, (93.2
to 97.3)% at 6, 8, 10, 12 atm respectively (p¼0.897). A computational model revealed
the MLC reduced hydraulic resistance to blood ﬂow by approximately 8% - 12% and
increased ﬂuid dispersion compared to the SLC.
Conclusions: A novel multi-lumen catheter may improve stem cell delivery by
preserving cell viability while improving dispersion.
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Different Dose of Stem Cells Transplantation in patients with Acute Myocardial
Infarction: a Meta-analysis
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Background: To evaluate whether stem cells transplantation improves global left
ventricular ejection fraction (LVEF) in patients with acute myocardial infarction(AMI)
and ﬁnd the most suitable dose to improve cardiac function.
Methods: Electronic searches include MEDLINE, The Cochrane Library, Embase,
CINAHL, CNKI and CBM, which retrieval time limit is from January 1990 to March
2014, unlimited practice. According to cell dosage and follow-up time, all trials were
divided into four or three subgroups. Data were analysed quantitatively using RevMan
5.2.Summary results are presented as weighted mean difference (WMD) with 95%
conﬁdence interval (CI). Collected individual trials data and undertook a meta-anal-
ysis to compare global Left Ventricular Ejection Fraction (LVEF).
Results: 33 papers (included 38 RCTs) were included in this study. The global LVEF
was obviously higher in stem cells transplantation group than control group(P <
0.0001). Subgroup analysis showed thatDLVEF in the dose of BMCs between 10 to the
8th power and 10 to the 9th power were signiﬁcantly higher than that in the control
groups (p< 0.05), which suggested that the global LVEF could improved after BMCs
therapy when the dose of BMSc in a certain range.When subgroups were in accordance
with the follow-up time, the results showed that with follow-up time prolonging, LVEF
was continuing to increase, and that persisted for more than 12 months (p< 0.01).
Conclusions: Stem cell transplantation after acute myocardial infarction could improve
the global LVEF in AMI patients. It may be effective when the dose of stem cells is
108-109. And the improvement of cardiac function would last more than 12 months.
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Background: The prevalence of atherosclerotic cardiovascular disease is higher in pa-
tients with type 2 diabetes, a disorder characterized by hyperinsulinemia and insulin
resistance. The role of hyperinsulinemia as an independent participant in the atherogenic
process has been controversial. Therefore, we examined whether insulin could regulate
the expression of scavenger receptors responsible for oxidised low-density lipoprotein
(oxLDL) uptake in DCs, a critical step in atherogenesis. In addition, we investigated the
impact of insulin onDCmaturation regardingchanges inphenotype and cytokine secretion.
Methods: Immature DCs were cultured with different concentrations of insulin
(1nmol/L, 10nmol/L, 100nmol/L) in the absence or presence of LY294002 or wart-
mannin for 24 hours. The expression of the scavenger receptors SR-A and CD36 was
determined by real-time PCR and western blot analysis. Furthermore, DCs were
incubated with DiI-labelled oxLDL. The DiI-oxLDL-incorporated fraction was
investigated by ﬂow cytometry analysis. Finally, ﬂow cytometry analysis was used to
investigate immunophenotypic protein expression (CD83 and CD11a). DC-differen-
tiation was evaluated using the expression of BDCA-1/-2 by ﬂow cytometer analysis.
Supernatant cytokine measurements were used for immune function assays.
Results: The incubation of DCs with insulin enhanced, in a dose-dependent manner,
the gene and protein expression of SR-A and CD36. This effect was partially abol-
ished by wartmannin, a phosphatidylinositol-3-OH kinase(PI3 kinase) inhibitor. But
LY294002 did not inhibit the effect of insulin on scavenger receptors’ expression.
High concentration of insulin increased the oxLDL-uptake capacity of DCs. Blockage
of the scavenger receptors SR-A and CD36 signiﬁcantly reduced oxLDL uptake.
Furthermore, high concentration of insulin induced DC-maturation and triggeredJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Codifferentiation of DCs in myeloid and plasmacytoid DCs. Finally, high concentration
of insulin decreased IL-10 secretion and increased IL-6 release.
Conclusions: This study suggests that hyperinsulinemia could promote DC activation
and oxLDL uptake and thus may contribute to atherosclerosis in patients with type 2
diabetes.Congenital Heart Disease - PFO and ASD
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Assessment Of Sleep Apnea In Patients With And Without A Patent Foramen
Ovale
Rubine Gevorgyan1, Mohammad K. Mojadidi1, Pooya Bokhoor2, Jonathan Tobis3
1UCLA School of Medicine, Los Angeles, CA, 2UCLA, Los Angeles, CA, 3David
Geffen School of Medicine, UCLA, Los Angeles, United States
Background: Obstructive sleep apnea (OSA) is a medical condition associated with
increased risk of cardiovascular mortality. It is reported that the prevalence of patent
foramen ovale (PFO) is increased in patients with OSA and may be involved in the
pathophysiology of OSA in some patients. The aim of this study was to assess the
presence of PFO in patients with OSA, and compare clinical characteristics and
parameters of the sleep studies of patients with and without PFO.
Methods: Patients with an abnormal polysomnogram seen at UCLA-Santa Monica
Sleep Medicine Clinic from January 2011 to September 2013 were enrolled in the
study. PFO diagnosis was made using transcranial Doppler (TCD) with an agitated
saline bubble study; a Spencer grade  3 was considered positive. Control subjects
were drawn from the population of patients referred for cardiac catheterization at the
UCLA Cardiac Catheterization Laboratory who underwent TCD. The frequency of
right-to-left shunt (RLS) in patients with OSA and the control group was evaluated.
The clinical characteristics and parameters of the polysomnogram were compared
between OSA patients with and without RLS.
Results: A total of 100 subjects with sleep apnea and 200 control patients participated
in the study. The prevalence of RLS was higher in patients with OSA than in the
control group (42% vs. 19%; p< 0.0001). When comparing patients with OSA, those
with PFO had a lower apnea hypopnea index (AHI) and fewer obstructive apnea and
hypopnea episodes. However, the baseline and nadir SaO2 were similar in both groups
and did not correlate with the level of RLS assessed by TCD.
Conclusions: PFO is found 2.2 times as frequently when patients have OSA
compared to a control population that was not tested for OSA. The severity of the
sleep apnea is not greater in the patients with OSA and PFO as evident by fewer apnea
and hypopnea episodes. But people who have OSA and a PFO are more likely to
become symptomatic earlier with an equivalent level of decrease in SaO2 which
would explain the increased prevalence of PFO in the pool of patients with OSA.
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Patent Foramen Ovale Closure in Patients with Orthodeoxia-Platypnea
Syndrome
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Background: Orthodeoxia-platypnea syndrome (OPS) is a rare clinical condition
characterized by hypoxemia in the upright position that is improved in the supine po-
sition. Although several etiologies of OPS exist, it is frequently associated with right-to-
left shunting of blood at the cardiac or pulmonary level, usually via a patent foramen
ovale (PFO). The aim of this study was to describe the outcomes of PFO closure in OPS.
Methods: Patients with OPS and a PFO referred to UCLA from 2001 to 2012 who
elected to have their PFO closed were assessed for the severity of their symptoms and
interval SaO2 changes, and classiﬁed according to the outcomes of “resolved,”
“improved” or “no change.” The results were compared between the three groups.
Results: Of 683 patients with PFO-associated conditions, 17 (2.5%) had OPS and
elected to close their PFO. Approximately a third of patients experienced complete
resolution of their dyspnea and hypoxemia, requiring no supplemental oxygen use
(improved SaO2 from baseline 8.5% when recumbent and 26% when upright; p¼0.03
and p< 0.0007 respectively). Another third experienced signiﬁcant improvement in
dyspnea, with baseline SaO2 improved to >93% and a smaller decrease in saturation
on sitting upright; they continued using supplemental oxygen (improved SaO2 from
baseline 4% when recumbent and 11% when upright, p¼0.29; p¼0.05 respectively).
Patients with no change after PFO closure predominantly had a pulmonary etiology
for their hypoxia, with elevated mean pulmonary pressures measured before closure
(51.416.8 mmHg, p¼0.06).ngenital Heart Disease - PFO and ASD B47
Variable
Resolved Improved No change
p-value
Mean  SD,
or N (%)
Mean  SD,
or N (%)
Mean  SD,
or N (%)
Total patients 6 (100%) 5 (100%) 6 (100%) -
Age 59.9  14.8 58.2  12 69.3  14 0.36
BMI (kg/m2) 28.7  6.8 31.6  4.5 29.1  7.6 0.74
SaO2 resting (%, pre-
procedure)
89.2  7.1 90.7  7.1 83.2 5.4 0.31
SaO2 in the upright position
(%, pre-procedure)
75.7  5.9 76.7  4.9 76  6.9 0.98
PFO canal height on cath
(mm)
10.3  3.2 8.5  3.1 11.5  4.9 0.61
Presence of atrial septal
aneurysm
0 (0%) 1 (20%) 2 (33.3%) 0.47
Presence of residual shunt 1 (16.7%) 1 (20%) 2 (33.3%) 0.47
SaO2 resting (%, post-
procedure)
96.8  1.9 94.4  1.5 87.2  3.5 <0.0001
SaO2 in the upright position
(%, post-procedure)
95.8  2.8 87.6  9.3 78.5  4.9 0.033
Mean pulmonary pressure
(mm Hg, pre-cath)
32.3  16.5 26.4  8.8 51.4  16.8 0.06
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: PFO closure may resolve symptomatic postural dyspnea and hypoxemia
and is an effective method for treating OPS.
TCT-160
The Genetic Basis Of Patent Foramen Ovale
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Background: Patent foramen ovale (PFO) is a remnant of normal fetal development
that persists inw25% of the population. It is a canal connecting the atria that allows the
transit of blood from venous to arterial circulation, bypassing the pulmonary circuit.
PFO is associated with cryptogenic stroke, migraine, visual auras, and other medical
conditions. Based on the analysis of family pedigrees, previous studies suggest that
PFO is an inherited condition. The aim of this novel study was to elucidate the speciﬁc
genes involved in maintaining patency of the foramen ovale after birth.
Methods: Medical records of patients with identiﬁed PFO were reviewed for family
history of PFO prevalence. Of 750 patients with PFO, 26 families were identiﬁed
having multiple members diagnosed with PFO. Five families (16 individuals) were
recruited for genetic testing. PFO was diagnosed using transcranial Doppler imaging
with agitated saline. Serum DNA was collected from the 16 subjects, and was
analyzed using exome sequencing. A two-tailed t-test analysis was used to compare
the mutations between the groups of those with PFO and those without PFO; p value
< 0.001 was considered as statistically signiﬁcant.
Results: In the ﬁve families (16 individuals) with available DNA samples, PFO was
found in 10 patients (62.5%). Exome sequencing revealed 25 mutations on 13 unique
chromosomes that demonstrated statistically signiﬁcant differences between the two
groups of those with PFO and those without PFO (p¼0.0002).
Conclusions: Genetic sequencing provides speciﬁc mutations that are linked to
patency of the foramen ovale. Further genetic testing on more families is ongoing.
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Transcatheter Closure of Atrial Septal Defect with Inferior Vena Cava Rim
Deﬁciency: Reconsideration of anatomical indication
Teiji Akagi1, Yasufumi Kijima1, Koji Nakagawa1, Yoichi Takaya1, Hiroki Oe2,
Hiroshi Ito3, Shunji Sano1
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Background: Recently revised instructions for use suggested that patients with
inferior vena cava (IVC) rim deﬁciency should be considered as contraindication of
transcatheter closure of atrial septal defect because of risk of cardiac erosion. Con-
ventional balloon sizing technique may produce the over sizing of device selection in
this anatomical condition. However, concern still remains the relationship between
IVC rim deﬁciency and complications.
Methods: Methods: From 2007 through 2013, 476 consecutive patients with ASD
were performed transcatheter ASD closure using Amplatzer Septal Occluder. Patients
were divided into 2 groups (with or without IVC rim deﬁciency) using trans-
esophageal echocardiographic evaluation. ASD diameter, selected device size, pro-
cedure success rate, complications (device migration, erosion) were evaluated. In
patients with IVC rim deﬁciency, 3-4 mm larger sized device was selected without
balloon sizing technique. Contrary, balloon sizing technique was used for device
selection in patients without IVC rim deﬁciency.B48 JACC Vol 64/11/Suppl B j September 1Results: Patients with IVC rim deﬁciency had signiﬁcantly larger defect size and
increased Qp/Qs ratio compared to patients without IVC rim deﬁciency. Although
patients with IVC rim deﬁciency had signiﬁcantly lower procedure success rate, more
than 90% patients with IVC deﬁciency could be treated with low complication rate
such as device migration or cardiac erosion. (Table)Conclusions: Under the appropriate device selection and device deployment tech-
nique, majority of patients with IVC rim deﬁciency can be treated by transcatheter
closure with low complication rate.
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Paradoxical embolic myocardial infarction
Franz X. Kleber1, Telse Hauschild2, Antonia Schulz3
1Cardio Centrum Berlin, Berlin, Germany, 2Ernst von Bergmann Klinikum, Potsdam,
Germany, 3Charité University Medicine, Berlin, Germany
Background: Despite several negative prospective randomized trials on the efﬁcacy
of patent foramen ovale (PFO) occlusions the discussion on the validity of these
studies and on new indications is ongoing. We investigated the risk of paradoxical
embolic myocardial infarction over a time period of more than 13 years.
Methods: Our effort to describe the epidemiology of paradoxical embolic myocardial
infarction included a retrospective and a prospective approach: We analyzed retro-
spectively the incidence of paradoxical coronary embolism over 10 years and then
prospectively undertook the effort to prove this using the same methodology over 39
months in another center. All patients with acute myocardial infarction (AMI) ac-
cording to ECG criteria and elevation of cardiac troponin or creatin kinase and normal
coronary arteries were screened for PFO and if no other reasons for the AMI could be
found after thorough work-up, were judged as presumed paradoxical embolism.
Results: In a retrospective analysis over 10 years amongst 4848 AMIs 22 patients
(0.45 %) were identiﬁed to have had presumed paradoxical embolic pathogenesis
based on strict criteria of absence of arrhythmias and virtual absence of atherosclerosis
in any vascular territory. To further elucidate the epidemiologic size of this disease
entity we prospectively studied 1654 AMIs in another tertiary referral center over a
time period of 39 months and found an incidence of 13 presumed paradoxical embolic
AMIs (0.79 %) based on application of the same criteria. The patients in the para-
doxical embolic cohorts were younger (45.7  11.5 years) as compared to the overall
AMI population (65.0  13.2 years), most likely based on the criteria applied
(exclusion of detectable atherosclerosis).
Conclusions: Paradoxcial embolism through a PFO is the most likely cause of AMI in
roughly 5/1000 patients. While this is a rather low rate, the incidence is still high
enough to warrent clinical attention.3–17, 2014 j TCT Abstracts/Congenital Heart Disease - PFO and ASD
